Key result
Metabolic syndrome was associated with significantly higher levels of inflammation and endothelial activation biomarkers compared to normal controls, irrespective of glycaemic status.
Cross-Sectional (n=319)
No
Metabolic syndrome is associated with enhanced inflammation and endothelial activation irrespective of glycemic status, suggesting that other components of the syndrome drive the pro-atherogenic state.
May signal heightened atherogenic risk in metabolic syndrome beyond glycemia; leaves open causal role and therapeutic targeting.
The objectives of this study were toinvestigate the inflammation and endothelial activationbiomarkers in subjects with metabolic syndrome (MS)subgroups irrespective ofstatus. Subjects (n=319) were categorized into MS subgroups [diabetes mellitus (MSDM),impaired fastig glucose (MSIFG) and normoglycemia (MSNG)] and normal controls (NC).Inflammatory biomarkers (high-sensitivity C-reactive protein and interleukin-6) andendothelial activation (soluble intercellular adhesion molecule-1, vascular cell adhesionmolecule-1 and E-selectin) were measured and compared between the groups. MS subjectshad significant increase in all biomarkers compared to NC subjects. Glycaemic status in MS subgroups did not show any association with the quartiles of all biomarkers, except forinterleukin-6. This may partially explain their increased coronary risk.
No takes yet. Share an insight, caveat, or question.
Osman et al. (2018) conducted a cross-sectional in Metabolic syndrome (n=319). Metabolic syndrome vs. Normal lean controls was evaluated on Inflammation and endothelial activation biomarkers (hsCRP, IL-6, sICAM-1, sVCAM-1, E-selectin). Metabolic syndrome was associated with significantly higher levels of inflammation and endothelial activation biomarkers compared to normal controls, irrespective of glycaemic status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: